Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 57-65

  Elzi, Luigia ^a   Marzolini, Catia ^a   Furrer, Hansjakob ^c   Ledergerber, Bruno ^b   Cavassini, Matthias ^d   Hirschel, Bernard ^e   Vernazza, Pietro ^f   Bernasconi, Enos ^g   Weber, Rainer ^b   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Children's Hospital St Gallen   (Switzerland)

^g Hospital of Lugano   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ADULT; AGE DISTRIBUTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SWITZERLAND;

ADENINE; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; BENZOXAZINES; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINONES; RISK FACTORS; SWITZERLAND; ZIDOVUDINE;

EID: 74549150032     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.432     Document Type: Article

References (42)

1. Egger M, May M, Chêne G, et al; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies [published correction appears in Lancet. 2002;360(9340):1178]. Lancet. 2002;360(9327):119-129.
2. May M, Sterne JA, Sabin C, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185-1197.
3. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293- 299.
4. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71.
5. Hammer SM, Eron JJ Jr, Reiss P, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
6. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: November 3, 2008. http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. Accessed January 30, 2009.
7. Vo TT, Ledergerber B, Keiser O, et al; Swiss HIV Cohort Study. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008;197(12):1685-1694.
8. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4):407-414.
9. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2006;41(3):385-392.
10. Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS. 2008;22(9):1039-1046.
11. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320-328.
12. Mocroft A, Phillips AN, Soriano V, et al; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005;21(9):743-752.
13. Keiser O, Fellay J, Opravil M, et al; Swiss HIV Cohort Study. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther. 2007;12(8):1157-1164.
14. Molina JM, Andrade-Villanueva J, Echevarria J, et al; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646-655.
15. Gallant JE, DeJesus E, Arribas JR, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
16. Hooshyar D, Napravnik S, Miller WC, Eron JJ Jr. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. AIDS. 2006;20(4):575-583.
17. Mocroft A, Rockstroh J, Soriano V, et al; EuroSIDA Study Group. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther. 2005;10(7):779-790.
18. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004;35(5):538-539.
19. Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27(4):336-343.
20. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-75.
21. Stöhr W, Back D, Dunn D, et al; Liverpool TDM Database; UK CHIC Study. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13(5):675-685.
22. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis. 2006;43(1):99-102.
23. Mallal S, Phillips E, Carosi G, et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
24. The Swiss HIV Cohort Study and the Mother and Child HIV Cohort Study. http://www.shcs.ch. Accessed January 30, 2009.
25. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
26. World Health Organization. International Classification of Diseases and Related Health Problems: 10th Revision (ICD-10). http://www.who.int/ classifications/apps/icd/icd10online/. Accessed January 30, 2009.
27. Kaufmann GR, Khanna N, Weber R, et al; Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antivir Ther. 2004;9(2):263-274.
28. Robison LS, Westfall AO, Mugavero MJ, et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses. 2008;24(11):1347-1355.
29. Yuan Y, L'italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156-162.
30. Park WB, Choe PG, Kim SH, et al. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Res Hum Retroviruses. 2007;23(6):794-800.
31. Keiser O, Orrell C, Egger M, et al; Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared [published correction appears in PLoS Med. 2008;5(9):e195]. PLoS Med. 2008;5(7):e148 http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2443185&blobtype=pdf. Accessed January 30, 2009.
32. HIV-pharmacogenomics Web site. http://www.hiv-pharmacogenomics.org. Accessed January 30, 2009.
33. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):194-201.
34. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender: differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr. 2008;47(4):441-448.
35. Marzolini C, Gibbons S, Elzi L, et al. Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study [abstract P141]. HIV Med. 2009;10(suppl 1):52.
36. Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents. 2005;26(1):88-91.
37. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev. 2009;11(1):30-38.
38. Dear Health Care Professional Letter: "clarification of risk factors for severe, lifethreatening and fatal hepatotoxicity with VIRAMUNE (nevirapine)", Boehringer Ingelheim. February 2004. http://www.fda.gov/ downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM166534.pdf. Accessed January 30, 2009.
39. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-829.
40. Rotger M, Taffe P, Bleiber G, et al; Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192(8):1381-1386.
41. University of Liverpool. Drug interaction charts. http://www.hiv- druginteractions.org/drug/drg-main.asp. Accessed January 30, 2009.
42. Boffito M, Acosta E, Burger D, et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10(4):469-477.